Unlike PSA, previous reports have suggested that MSMB levels are unaffected by hormone ablation therapy frequently used in prostate cancer treatment and we need to determine if MSMB might be useful in monitoring disease burden in patients undergoing various forms of treatment [2], [3], [4]. This evidence concerns the gene MSMB and prostate carcinoma.